Apraglutide met the primary endpoint of relative change from baseline in actual weekly parenteral support (PS) volume at week 24, driven by both stoma and colon-in-continuity populations –
– Apraglutide also showed a clinically meaningful improvement at week 24, with patients achieving at least one day off PS per week –
– Apraglutide was generally well-tolerated, and the safety profile was consistent with previously-reported studies of apraglutide in this patient population –
– Ironwood to submit new drug application and other regulatory filings for apraglutide as a once-weekly GLP-2 analog for use in adult patients with SBS who are dependent on PS –